

## CV Univ. Prof. Dr. Richard Greil

### 1-Personal Data

#### Univ. Prof. Dr. Richard Greil

Head: III<sup>rd</sup> Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, [Email:r.greil@salk.at](mailto:r.greil@salk.at), [www.onkologie-salzburg.com](http://www.onkologie-salzburg.com)

Head: Salzburg Cancer Research Institute [www.scri.or.at](http://www.scri.or.at)

Head: Cancer Cluster Salzburg [www.cancercluster-salzburg.at](http://www.cancercluster-salzburg.at)

### 2-Main areas of research

#### 2.1 Clinical Cancer Research

The main aim is to provide novel types of therapy to the broadest possible populations of patients with hematologic and solid cancers. Since my appointment as the head of the III<sup>rd</sup> Medical Department at the Paracelsus Medical University Salzburg I have established and headed the Salzburg Cancer Research Institute with its Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT) Gesmbh which organizes the trials performed at the Department. During this time, more than 9,000 patients have been cared for within clinical trials in my Department and the SCRI –CCCIT, respectively. Clinical trials involve all phases of trials, all types of systemic therapy and comprise both, trials sponsored by the pharmaceutical industry as well as investigator-initiated trials. The malignant diseases are mainly: all types of hematological cancers, i.e. all types of leukemias and lymphomas, breast cancer, head and neck cancer, gastrointestinal and lung cancer.

Within the AGMT Gesmbh we are planning and performing phase I-III trials as well as large clinical registries on a national and international basis. Between 2005 and 2017 5,358 patients have been included in programs of the AGMT.

Quality of life is a relevant aspect in many of our trials, both investigator-initiated as well as industry-sponsored (for details see publication record). In this aspect, a very long-lasting and productive cooperation is established with the Mmedical University of Innsbruck (Prof. Holzner), but also international trial groups like the German Hodgkin Study Group and the Swedish Breast Cancer Group.

#### 2.2 Translational Research

The main focus is: tumor immunology, mechanisms of tumor cell homing and apoptosis regulation in CLL (chronic lymphocytic leukemia) and AML (Acute myeloid leukemia). In addition, biomarker development for response prediction in breast cancer and head and neck cancer are important areas of research as is genomic medicine.

### Publications

#### Publikationen

■Peer-reviewte Pubmed Publikationen	408	(pubmed, 1/2018)
■Impact Factor	3145,05	
■H Factor	68	(Google Scholar, 1/2008)
■Citations	21960	(Google Scholar, 1/2018)

### 3-Academic CV

- 1983 Human Medicine at the Leopold Franzens University Innsbruck
- 1983 Promotion *Sub auspiciis praesidentis rei publicae Austriae*
- 1990 Board Certification for Internal Medicine
- 1992 Habilitation for Internal Medicine at the Leopold Franzens University Innsbruck
- 1995 Board Certification for Hematology and Medical Oncology
- 1997 ao. Professorship at the Leopold Franzens-University Innsbruck
- 1997 Deputy Head of the Department of Hematology and Medical Oncology at the University of Innsbruck
- 1998 Founding Member of the Tyrolean Cancer Research Institute
- 2001-2004 Scientific Director of the Tyrolean Cancer Research Institute

## Since the Appointment for the current position in Salzburg

- 2004 Head of the III<sup>rd</sup> Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Oncologic Center at the Paracelsus Medical University Salzburg
- 2004 Founder of the Center for *Clinical Cancer and Immunology Trials (CCCIT)* at the at the III<sup>rd</sup> Medical Department
- 2005 Founder and Head of the Laboratory for Immunological and Molecular Cancer Research (LIMCR) and the Laboratory of Molecular Cytology at the III<sup>rd</sup> Medical Department
- 2005 Board Certification for Rheumatology
- 2004 ff President and Scientific Head of the *Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)-GesmbH (Clinical Trial Group)*
- 2004ff Vice Preseident of the *Austrian Breast and Colorectal Cancer Study Group (ABCSG)*
- 2007 Board Certification for Infectious Diseases and Tropical Medicine
- 2007 Head of the Stem Cell Laboratory at the III<sup>rd</sup> Medical Department
- 2011-2017 Member of the Board of the Austrian Science Foundation (FWF, Ersatzmitglied Kurtaorium)
- 2012-2017 Vice President of the Austrian Society of Hematology and Medical Oncology
- 2013 Scientific Head of the *Salzburg Cancer Research Institute GmbH*
- 2013ff Head of the *Cancer Cluster Salzburg*
- 2013-14 Medical Director of the Cancer Rehabilitation Hospital in St. Veit in Salzburg
- Member of the Guideline Committee of the Austrian, German and Swiss Societies of Heatology and Oncology and Coauthor of Onkopedia guidelines for Breast Cancer; Chronic lymphocytic Leukemia; Trasnltional Medicine
- 2017 Honorary Professor at the Natural Science Faculty oft he Paris-Lodron University Salzburg, Austria
- 2017 Head of the Smart Specialization Center-Cancer Cluster Salzburg

## 4 Awards and Invitations

### 4.1 invitations for lectures

- 2009 European Society of Medical Oncology (ESMO)/ECCO Meeting Berlin, „Individualized cancer therapy, The Pro and Con Debate“
- 2010 Educational at the Annual Conference oft he Austrian, German and Swiss Societies of Hematology and Oncology “Novel drugs in CLL”□
- 2011 The Feinstein Institute in New York, “The Role of the Microenvironment in CLL”
- 2012 Early Breast Cancer Conference Vienna (EBCC): “The Management of Her2/neu overexpression in breast cancer”
- 2012 The Pharmacogenomics Working Party oft he European Medicine Agency (EMA), in Salzburg: “Pharmacogenomics and Pharmacogenetics in Oncology: Critical Comments in the era of transition towards personalized medicine”
- 2014 American Society of Hematology (ASH) Meeting, oral presentation on „Mabtenance treatment in CLL, AGMT 8a Mabtenance trial“
- 2016 German, Austrian and Swiss Societies for Hematology and Oncology Annual Meeting in Leipzig “The future for the treatment of CLL is chemofreee”

### 4.2 Scientific awards (selection and including publications of members of the team with coauthorship of RG)

- Wolfgang Denk award of the Austrian Society of Hematology and Oncology (1988, 2008)
- Wilhelm Türk award of the Austrian Society of Hematology and Medical Oncology (1991,2010, 2013)
- Hoechst and Sanofi Aventis Foundation (1989,2009, 2010,2011,2013,2014)

### 4.3 Review activities for programs

- European Union Framework Programme
- Medical Research Council (MRC), UK
- French National Cancer Institute
- Italian Ministry of Health
- Mildred Scheel Foundation off he German Cancer Aid

#### 4.4 Review activities for journals

Lancet, Lancet Oncology, Lancet Haematology, J Exp Medicine, Blood

#### 4.4 Memberships in organizations

American Society of Hematology (ASH), American Society of Oncology (ASCO), American Association for Cancer Research (AACR), European Society for Medical Oncology (ESMO), European Hematology Association (EHA)

#### 4.3 Scientific Grants

- at FWF, FFG, EU, ÖNB, PMU, City of Salzburg

### ***5 Some of the most important publications during lifetime***

Greil R, Fasching B, Loidl P, Huber H. Expression of the c-myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. **Blood.** **1991** Jul 1;78(1):180-91. PubMed PMID: 2070052.

Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, **Greil R.** Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. **Cancer Res.** **1997** Aug 15;57(16):3331-4. PubMed PMID: 9269989.

Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, **Greil R.** Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. **Blood.** **1997** Jul 1;90(1):12-20. PubMed PMID: 9207432.

Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, **Greil R.** Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. **Blood.** **1998** Jun 1;91(11):4273-81. PubMed PMID: 9596676.

Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, Kofler R, Csordas A, **Greil R.** Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. **FASEB J.** **2001** Jul;15(9):1613-5. PubMed PMID: 11427503

Pleyer L, Egle A, Hartmann TN, **Greil R.** Molecular and cellular mechanisms of CLL: novel therapeutic approaches. **Nat Rev Clin Oncol.** **2009** Jul;6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2. Review. PubMed PMID: 19488076.

Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, **Greil R.** microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. **Blood.** **2010** May 27;115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20. PubMed PMID: 20089965.

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, **Greil R**; ABCSG-12 Trial Investigators, Marth C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. **N Engl J Med.** 2009 Feb 12;360(7):679-91. doi: 10.1056/NEJMoa0806285. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, **Greil R**, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. **N Engl J Med.** 2010 Aug 12;363(7):640-52.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, **Greil R**; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. **Lancet Oncol.** 2011 Jul;12(7):631-41.

Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, **Greil R**, Hartmann TN. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. *Blood.* 2014 Apr 3;123(14):2181-8. doi: 10.1182/blood-2013-08-523563. Epub 2014 Feb 5. PubMed PMID: 24501217.

Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmolzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. **Leukemia.** 2014 Apr;28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20. PubMed PMID: 24441290.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, **Greil R**, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artnar-Matuschek S, Fitzal F, Marth C, Sevela P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. **Lancet.** 2015 Aug 1;386(9992):433-43.

**Greil R**, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubíško M, Jäger U, Fridrik M, Pecherstorfer M, Králíková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. **Lancet Haematol.** 2016 Jul;3(7):e317-29.

Borchmann P, Goergen H, Kobe C, Lohri A, **Greil R**, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial

by the German Hodgkin Study Group. **Lancet.** 2017 Oct 20. pii: S0140-6736(17)32134-7. doi: 10.1016/S0140-6736(17)32134-7. [Epub ahead of print] PubMed PMID: 29061295.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Anđel J, **Greil R.** Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. *Int J Mol Sci.* 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415. PubMed PMID: 28212292; PubMed Central PMCID: PMC5343949

### **6-List of publications during the last 5 years [only Pubmed-listed publications are given September 2012 until October 2017]**

Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, **Greil R.** DNA Methylation Signatures Predicting Bevacizumab Efficacy In Metastatic Breast Cancer. *Theranostics*, 2018, in the press

Huemer F, Thaler J, Piringer G, Hackl H, Pleyer L, Hufnagl C, Weiss L, **Greil R.** Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). *BMC Cancer.* 2018 Jan 3;18(1):11. doi:10.1186/s12885-017-3955-4. PubMed PMID: 29298682.

Gassner FM, Schubert M, Rebhandl S, Spandl K, Zaborsky N, Catakovic K, Blaimer S, Hebenstreit D, **Greil R,** Geisberger R. Repair of DNA breaks is imprecise and biased towards joining of incompatible DNA ends in chronic lymphocytic leukemia. *Mol Cancer Res,* 2017, 2017 Dec 8. pii: molcanres.0373.2017. doi: 10.1158/1541-7786.MCR-17-0373

Bolger GT, Licollari A, Tan A, **Greil R,** Pleyer L, Vcelar B, Majeed M, Sordillo P. Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. *Anticancer Research,* 2018 Jan;38(1):121-130. PubMed PMID: 29277764.

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, **Greil R,** Geisberger R. TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. *Oncoimmunology.* 2017 Sep 21;7(1):e1371399. doi: 10.1080/2162402X.2017.1371399. eCollection 2017. PubMed PMID: 29296521; PubMed Central PMCID: PMC5739567

Weiss L, Huemer F, **Greil R.** ASCO-update: gastrointestinal tumors. *Memo.* 2017;10(4):240-243. doi: 10.1007/s12254-017-0366-9. Epub 2017 Nov 13. Review. PubMed PMID: 29250204; PubMed Central PMCID: PMC5725513.

Magnes T, Egle A, **Greil R,** Melchardt T. Update on squamous cell carcinoma of the head and neck: ASCO annual meeting 2017. *Memo.* 2017;10(4):220-223. doi: 10.1007/s12254-017-0358-9. Epub 2017 Oct 20. Review. PubMed PMID: 29250200; PubMed Central PMCID: PMC5725515.

Gampenrieder SP, Westphal T, **Greil R**. Antiangiogenic therapy in breast cancer. *Memo*. 2017;10(4):194-201. doi: 10.1007/s12254-017-0362-0. Epub 2017 Nov 6. Review. PubMed PMID: 29250196; PubMed Central PMCID: PMC5725520.

Piringer G, Fridrik M, Fridrik A, Leihner A, Zabernigg A, **Greil R**, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSSG). A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients. *Support Care Cancer*. 2017 Nov 22. doi: 10.1007/s00520-017-3961-8. [Epub ahead of print] PubMed PMID: 29168033.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribí K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol*. 2017 Nov 17. pii: S1470-2045(17)30715-5. doi: 10.1016/S1470-2045(17)30715-5. [Epub ahead of print] PubMed PMID: 29158011.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. *N Engl J Med*. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830. PubMed PMID: 29117498.

Borchmann P, Goergen H, Kobe C, Lohri A, **Greil R**, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. *Lancet*. 2017 Oct 20. pii: S0140-6736(17)32134-7. doi: 10.1016/S0140-6736(17)32134-7. [Epub ahead of print] PubMed PMID: 29061295.

Wöll E, Thaler J, Keil F, Gruenberger B, Hejna M, Eisterer W, Fridrik MA, Ulmer H, Trommet V, Huemer F, Weiss L, **Greil R**. Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT\_GASTRIC-3. *Anticancer Res*. 2017 Oct;37(10):5553-5558. PubMed PMID: 28982869.

Riedl D, Giesinger JM, Wintner LM, Loth FL, Rumpold G, **Greil R**, Nickels A, Licht T, Holzner B. Improvement of quality of life and psychological distress after inpatient cancer rehabilitation: Results of a longitudinal observational study. *Wien Klin Wochenschr*. 2017 Sep 15. doi: 10.1007/s00508-017-1266-z. [Epub ahead of print] PubMed PMID: 28916897; PubMed Central PMCID: PMC5630652.

Burgstaller S, Stauder R, Kuehr T, Lang A, Machherndl-Spandl S, Mayrbaeurl B, Noesslinger T, Petzer A, Valent P, **Greil R**, Thaler J. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT\_CMML-1. *Leuk Lymphoma*. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070. [Epub ahead of print] PubMed PMID: 28853315.

Falantes J, Pleyer L, Thépot S, Almeida AM, Maurillo L, Martínez-Robles V, Stauder R, Itzykson R, Pinto R, Venditti A, Bargay J, Burgstaller S, Martínez MP, Seegers V, Cortesão E, Foncillas MÁ, Gardin C, Montesinos P, Musto P, Fenaux P, **Greil R**, Sanz MA, Ramos F; European ALMA + Investigators. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). *Leuk Lymphoma*. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854. [Epub ahead of print] PubMed PMID: 28838276.

Gampenrieder SP, Rinnerthaler G, **Greil R**. SABCS 2016: systemic therapy for metastatic breast cancer. *Memo*. 2017;10(2):86-89. doi: 10.1007/s12254-017-0326-4. Epub 2017 Apr 4. Review. PubMed PMID: 28725277; PubMed Central PMCID: PMC5493725.

Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggli A, **Greil R**, Egle A. The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. *Pharmacogenomics J*. 2017 Jul 18. doi: 10.1038/tpj.2017.37. [Epub ahead of print] PubMed PMID: 28719596.

Magnes T, Melchardt T, Weiss L, Mittermair C, Neureiter D, Klieser E, Gampenrieder S, Moser G, Gaggli A, **Greil R**, Egle A. Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy. *PLoS One*. 2017 Jul 7;12(7):e0180995. doi: 10.1371/journal.pone.0180995. eCollection 2017. PubMed PMID: 28686697; PubMed Central PMCID: PMC5501656.

Bolger GT, Licollari A, Tan A, **Greil R**, Vcelar B, Majeed M, Helson L. Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. *Anticancer Res*. 2017 Jul;37(7):3483-3492. PubMed PMID: 28668837.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSCG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. *Eur J Cancer*. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23. PubMed PMID: 28651158.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast

Cancer. *N Engl J Med*. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643. Epub 2017 Jun 5. Erratum in: *N Engl J Med*. 2017 Aug 17;377(7):702. PubMed PMID: 28581356; PubMed Central PMCID: PMC5538020.

Padberg S, Mick I, Frenzel C, **Greil R**, Hilberath J, Schaefer C. Transient congenital dilated cardiomyopathy after maternal R-CHOP chemotherapy during pregnancy. *Reprod Toxicol*. 2017 Aug;71:146-149. doi: 10.1016/j.reprotox.2017.05.008. Epub 2017 May 25. PubMed PMID: 28552383.

Leisch M, Weiss L, Lindlbauer N, Jungbauer C, Egle A, Rohde E, **Greil R**, Grabmer C, Pleyer L. Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience. *Leuk Res*. 2017 Aug;59:12-19. doi: 10.1016/j.leukres.2017.05.006. Epub 2017 May 9. PubMed PMID: 28535394.

Eisterer W, Piringer G, DE Vries A, Öfner D, **Greil R**, Tschmelitsch J, Samonigg H, Sölkner L, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study. *Anticancer Res*. 2017 May;37(5):2683-2691. PubMed PMID: 28476845.

Weiss L, Melchardt T, Egle A, Hopfinger G, Hackl H, **Greil R**, Barth J, Rummel M. Influence of body mass index on survival in indolent and mantle cell lymphomas: analysis of the StiL NHL1 trial. *Ann Hematol*. 2017 Jul;96(7):1155-1162. doi: 10.1007/s00277-017-3003-0. Epub 2017 Apr 30. PubMed PMID: 28456850; PubMed Central PMCID: PMC5486799.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, **Greil R**, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. *J Clin Oncol*. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20. PubMed PMID: 28426350.

Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippel P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, **Greil R**, Pleyer L. Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. *Int J Mol Sci*. 2017 Apr 14;18(4). pii: E837. doi: 10.3390/ijms18040837. PubMed PMID: 28420120; PubMed Central PMCID: PMC5412421.

Wolff F, Leisch M, **Greil R**, Risch A, Pleyer L. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. *Cell Commun Signal*. 2017 Mar 31;15(1):13. doi: 10.1186/s12964-017-0168-z. Review. PubMed PMID: 28359286; PubMed Central PMCID: PMC5374693.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, **Greil R**, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert



A. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP(escalated) alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. *Lancet Oncol.* 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22. PubMed PMID: 28236583.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, **Greil R**. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. *Int J Mol Sci.* 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415. PubMed PMID: 28212292; PubMed Central PMCID: PMC5343949.

**Greil R**, Hutterer E, Hartmann TN, Pleyer L. Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. *Cell Commun Signal.* 2017 Jan 19;15(1):5. doi: 10.1186/s12964-016-0155-9. Review. PubMed PMID: 28100240; PubMed Central PMCID: PMC5244547.

Ludwig H, Weisel K, Petrucci MT, Leleu X, Cafro AM, Garderet L, Leitgeb C, Foa R, **Greil R**, Yakoub-Agha I, Zboralski D, Vauléon S, Dümmler T, Beyer D, Kruschinski A, Riecke K, Baumann M, Engelhardt M. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. *Leukemia.* 2017 Apr;31(4):997-1000. doi: 10.1038/leu.2017.5. Epub 2017 Jan 11. PubMed PMID: 28074071; PubMed Central PMCID: PMC5383929.

Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, Halbsguth TV, Meissner J, **Greil R**, Moosmann P, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P. Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. *J Clin Oncol.* 2016 Dec 20;34(36):4329-4337. Epub 2016 Oct 31. PubMed PMID: 27998235.

Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, Mayerhoefer ME, Simonitsch-Klupp I, Melchardt T, **Greil R**, Raderer M; AGMT Investigators. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma. *Blood.* 2017 Jan 19;129(3):383-385. doi: 10.1182/blood-2016-06-720599. Epub 2016 Nov 22. PubMed PMID: 27879257.

Huemer F, Dejaco M, Grabmer C, Melchardt T, Neureiter D, Mayer G, Egle A, **Greil R**, Weiss L. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report. *Wien Klin Wochenschr.* 2017 Feb;129(3-4):141-144. doi: 10.1007/s00508-016-1124-4. PubMed PMID: 27878613; PubMed Central PMCID: PMC5318479.

Pikija S, Pilz G, Gschwandtner G, Rösler C, Schlick K, **Greil R**, Sellner J. Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. *Front Neurol.* 2016 Nov 7;7:196. eCollection 2016. PubMed PMID: 27872609; PubMed Central PMCID: PMC5098172.

Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, **Greil R**, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG), the German Breast Group (GBG), and the Austrian Breast & Colorectal Cancer Study Group

(ABCSCG). Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial. *JAMA*. 2016 Nov 8;316(18):1888-1896. doi: 10.1001/jama.2016.15865. PubMed PMID: 27825007.

Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, **Greil R**, Jöhner K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. *J Hematol Oncol*. 2016 Nov 3;9(1):116. PubMed PMID: 27809856; PubMed Central PMCID: PMC5093947.

Taylor N, Kremser I, Auer S, Hoermann G, **Greil R**, Haschke-Becher E, Esterbauer H, Kenner L, Oberkofler H. Hemeoxygenase-1 as a Novel Driver in Ritonavir-Induced Insulin Resistance in HIV-1-Infected Patients. *J Acquir Immune Defic Syndr*. 2017 May 1;75(1):e13-e20. doi: 10.1097/QAI.0000000000001223. PubMed PMID: 27798431; PubMed Central PMCID: PMC5298192.

Karhaus M, Hofheinz RD, Mineur L, Letocha H, **Greil R**, Thaler J, Fernebro E, Oliner KS, Boedigheimer M, Twomey B, Zhang Y, Demonty G, Köhne CH. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. *Br J Cancer*. 2016 Nov 8;115(10):1215-1222. doi: 10.1038/bjc.2016.343. Epub 2016 Oct 20. PubMed PMID: 27764839; PubMed Central PMCID: PMC5104899.

Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, Weiss L, Gary T, Neureiter D, Klieser E, **Greil R**, Neumeister P, Egle A, Pichler M. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. *Br J Cancer*. 2016 Nov 8;115(10):1264-1272. doi: 10.1038/bjc.2016.325. Epub 2016 Oct 20. PubMed PMID: 27764838; PubMed Central PMCID: PMC5104895.

Thangavadivel S, Zelle-Rieser C, Olivier A, Postert B, Untergasser G, Kern J, Brunner A, Gunsilius E, Biedermann R, Hajek R, Pour L, Willenbacher W, **Greil R**, Jöhner K. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma. *Oncotarget*. 2016 Nov 29;7(48):78605-78618. doi: 10.18632/oncotarget.12522. PubMed PMID: 27732933; PubMed Central PMCID: PMC5346663.

Rachar V, Czejka M, Kitzmueller M, Buchner P, Lichtneckert M, **Greil R**, Geiler H, Dittrich C. Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. *Anticancer Res*. 2016 Sep;36(9):4715-23. PubMed PMID: 27630318.

Zielinski C, Láng I, Inbar M, Kahán Z, **Greil R**, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzalka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. *Lancet Oncol*. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5. PubMed PMID: 27501767.

Weiss L, Huemer F, Mlineritsch B, **Greil R**. Immune checkpoint blockade in ovarian cancer. *Memo*. 2016;9:82-84. Epub 2016 Jun 2. Review. PubMed PMID: 27429660; PubMed Central PMCID: PMC4923079.

Gampenrieder SP, Rinnerthaler G, **Greil R**. CDK4/6 inhibition in luminal breast cancer. *Memo*. 2016;9:76-81. Epub 2016 Jun 20. Review. PubMed PMID: 27429659;

PubMed Central PMCID: PMC4923084.

Zaborsky N, Gassner FJ, Asslaber D, Reinthaler P, Denk U, Flenady S, Hofbauer JP, Danner B, Rebhandl S, Harrer A, Geisberger R, **Greil R**, Egle A. CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. *Oncotarget*. 2016 Aug 2;7(31):49459-49469. doi: 10.18632/oncotarget.10372. PubMed PMID: 27385215; PubMed Central PMCID: PMC5226521.

**Greil R**, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubíško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. *Lancet Haematol*. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16. PubMed PMID: 27374465.

Pleyer L, Valent P, **Greil R**. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? *Int J Mol Sci*. 2016 Jun 27;17(7). pii: E1009. doi: 10.3390/ijms17071009. Review. PubMed PMID: 27355944; PubMed Central PMCID: PMC4964385.

Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, **Greil R**, Weigert O, Egle A. Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. *Oncotarget*. 2016 Aug 9;7(32):51494-51502. doi: 10.18632/oncotarget.9860. PubMed PMID: 27285986; PubMed Central PMCID: PMC5239491.

Leleu X, Terpos E, Sanz RG, Cooney J, O'Gorman P, Minarik J, **Greil R**, Williams C, Gray D, Szabo Z. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). *Am J Hematol*. 2016 Aug;91(8):806-11. doi: 10.1002/ajh.24416. Epub 2016 Jun 8. PubMed PMID: 27169523.

Magnes T, Melchardt T, Weiss L, Hufnagl C, **Greil R**, Egle A. Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping. *J Clin Oncol*. 2016 Jul 10;34(20):2433-4. doi: 10.1200/JCO.2016.66.6057. Epub 2016 May 9. PubMed PMID: 27161962.

Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Monzo Fuentes C, Morre P, Hauser-Kronberger C, Mlineritsch B, **Greil R**. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer. *Pharmacogenomics J*. 2017 Jul;17(4):344-350. doi: 10.1038/tpj.2016.25. Epub 2016 May 3. PubMed PMID: 27139155.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Oral Ixazomib,

Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med.* 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. PubMed PMID: 27119237.

Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Geissler D, Sperr WR, Hojas S, Rogulj IM, Anđel J, **Greil R.** Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. *J Hematol Oncol.* 2016 Apr 16;9:39. doi: 10.1186/s13045-016-0263-4. PubMed PMID: 27084507; PubMed Central PMCID: PMC4833933.

Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, Anđel J, Burgstaller S, Krieger O, Oberaigner W, Sihorsch K, **Greil R.** Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). *Eur J Cancer.* 2016 May;58:112-21. doi: 10.1016/j.ejca.2016.02.004. Epub 2016 Mar 15. PubMed PMID: 26990931.

Willenbacher W, Thangavadivel S, **Greil R,** Willenbacher E, Weger R, Manzl C, Jöhner K, Brunner A. Low Beclin-1 expression predicts improved overall survival in patients treated with immunomodulatory drugs for multiple myeloma and identifies autophagy inhibition as a promising potentially druggable new therapeutic target: an analysis from The Austrian Myeloma Registry (AMR). *Leuk Lymphoma.* 2016 Oct;57(10):2330-41. doi: 10.3109/10428194.2016.1144880. Epub 2016 Feb 16. PubMed PMID: 26880040.

Krenn PW, Hofbauer SW, Pucher S, Hutterer E, Hinterseer E, Denk U, Aszlauer D, Ganghammer S, Sternberg C, Neureiter D, Aberger F, Wickström SA, Egle A, **Greil R,** Hartmann TN. ILK Induction in Lymphoid Organs by a TNF $\alpha$ -NF- $\kappa$ B-Regulated Pathway Promotes the Development of Chronic Lymphocytic Leukemia. *Cancer Res.* 2016 Apr 15;76(8):2186-96. doi: 10.1158/0008-5472.CAN-15-3379. Epub 2016 Feb 2. PubMed PMID: 26837762.

Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, **Greil R,** von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. *Blood.* 2016 May 5;127(18):2189-92. doi: 10.1182/blood-2015-11-681064. Epub 2016 Feb 1. PubMed PMID: 26834240.

Rinnerthaler G, Hackl H, Gampenrieder SP, Hamacher F, Hufnagl C, Hauser-Kronberger C, Zehentmayr F, Fastner G, Sedlmayer F, Mlineritsch B, **Greil R.** miR-16-5p Is a Stably-Expressed Housekeeping MicroRNA in Breast Cancer Tissues from Primary Tumors and from Metastatic Sites. *Int J Mol Sci.* 2016 Jan 26;17(2). pii: E156. doi: 10.3390/ijms17020156. PubMed PMID: 26821018; PubMed Central PMCID: PMC4783890.

Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, **Greil R,** Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P. DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon

Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. *JAMA Oncol.* 2016 Jan 21. doi: 10.1001/jamaoncol.2015.5392. [Epub ahead of print] PubMed PMID: 26794347.

Huemer F, Melchardt T, Tränkenschuh W, Neureiter D, Moser G, Magnes T, Weiss L, Schlattau A, Hufnagl C, Ricken G, Höftberger R, **Greil R**, Egle A. Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer. *BMC Cancer.* 2015 Dec 22;15:996. doi: 10.1186/s12885-015-2020-4. PubMed PMID: 26694863; PubMed Central PMCID: PMC4687318.

Forbes JF, Sestak I, Howell A, Bonanni B, Bundred N, Levy C, von Minckwitz G, Eiermann W, Neven P, Stierer M, Holcombe C, Coleman RE, Jones L, Ellis I, Cuzick J; IBIS-II investigators. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. *Lancet.* 2016 Feb 27;387(10021):866-73. doi: 10.1016/S0140-6736(15)01129-0. Epub 2015 Dec 11. PubMed PMID: 26686313; PubMed Central PMCID: PMC4769326.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Schlick K, Huemer F, Deutsch A, Neumeister P, **Greil R**, Pichler M, Egle A. Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI. *J Natl Compr Canc Netw.* 2015 Dec;13(12):1501-8. PubMed PMID: 26656519.

Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. *Ann Oncol.* 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. PubMed PMID: 26646759; PubMed Central PMCID: PMC4769992.

Troppan KT, Melchardt T, Wenzl K, Schlick K, Deutsch A, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Tränkenschuh W, **Greil R**, Neumeister P, Egle A, Pichler M. The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. *J Clin Pathol.* 2016 Apr;69(4):326-30. doi: 10.1136/jclinpath-2015-203356. Epub 2015 Dec 7. PubMed PMID: 26644520.

Schlick K, Grundbichler M, Auberger J, Kern JM, Hell M, Hohla F, Hopfinger G, **Greil R**. Cytomegalovirus reactivation and its clinical impact in patients with solid tumors. *Infect Agent Cancer.* 2015 Dec 3;10:45. doi: 10.1186/s13027-015-0039-4. eCollection 2015. PubMed PMID: 26635891; PubMed Central PMCID: PMC4668639.

Ganghammer S, Gutjahr J, Hutterer E, Krenn PW, Pucher S, Zelle-Rieser C, Jöhrer K, Wijtmans M, Leurs R, Smit MJ, Gattei V, **Greil R**, Hartmann TN. Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. *Haematologica.* 2016 Mar;101(3):e99-102. doi: 10.3324/haematol.2015.133470. Epub 2015 Nov 20. PubMed PMID: 26589908; PubMed Central PMCID: PMC4815737.

Leierer G, Grabmeier-Pfistershammer K, Steuer A, Geit M, Sarcletti M, Haas B, Kanatschnig M, Rappold M, Zangerle R, Ledergerber B, Taylor N; Austrian HIV Cohort Study Group. Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study. *PLoS One.* 2015 Nov

13;10(11):e0142923. doi: 10.1371/journal.pone.0142923. eCollection 2015. PubMed PMID: 26566025; PubMed Central PMCID: PMC4643888.

Kocher T, Asslaber D, Zaborsky N, Flenady S, Denk U, Reinthaler P, Ablinger M, Geisberger R, Bauer JW, Seiffert M, Hartmann TN, **Greil R**, Egle A, Piñón Hofbauer J. CD4+ T cells, but not non-classical monocytes, are dispensable for the development of chronic lymphocytic leukemia in the TCL1-tg murine model. *Leukemia*. 2016 Jun;30(6):1409-13. doi: 10.1038/leu.2015.307. Epub 2015 Nov 2. PubMed PMID: 26522084; PubMed Central PMCID: PMC4895160.

Jaeger U, Praxmarer M, **Greil R**; AGMT-NHL13 investigators. Response to comment by P. Vassilakopoulos and colleagues. *Haematologica*. 2015 Nov;100(11):e482. doi: 10.3324/haematol.2015.134288. PubMed PMID: 26521299; PubMed Central PMCID: PMC4825306.

62: Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Tränkenschuh W, **Greil R**, Egle A. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. *BMC Cancer*. 2015 Oct 16;15:725. doi: 10.1186/s12885-015-1776-x. PubMed PMID: 26475344; PubMed Central PMCID: PMC4609094.

Aschauer G, **Greil R**, Linkesch W, Nösslinger T, Stauder R, Burgstaller S, Fiegl M, Fridrik M, Girschikofsky M, Keil F, Petzer A. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria. *Clin Lymphoma Myeloma Leuk*. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5. PubMed PMID: 26422252.

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, **Greil R**. Ropeginterferon alfa-2b, a novel IFN $\alpha$ -2b, induces high response rates with low toxicity in patients with polycythemia vera. *Blood*. 2015 Oct 8;126(15):1762-9. doi: 10.1182/blood-2015-04-637280. Epub 2015 Aug 10. PubMed PMID: 26261238; PubMed Central PMCID: PMC4608390.

Ludwig H, **Greil R**, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. *Br J Haematol*. 2015 Nov;171(3):344-54. doi: 10.1111/bjh.13582. Epub 2015 Jul 7. PubMed PMID: 26153365; PubMed Central PMCID: PMC4758383.

Hofbauer SW, Krenn PW, Piñón Hofbauer J, Pucher S, Asslaber D, Egle A, Hartmann TN, **Greil R**. The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. *Br J Haematol*. 2016 Mar;172(5):815-9. doi: 10.1111/bjh.13542. Epub 2015 Jul 6. PubMed PMID: 26147087; PubMed Central PMCID: PMC4832298.

Rebhandl S, Huemer M, **Greil R**, Geisberger R. AID/APOBEC deaminases and cancer. *Oncoscience*. 2015 Apr 28;2(4):320-33. eCollection 2015. Review. PubMed PMID: 26097867; PubMed Central PMCID: PMC4468319.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA,

Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovska V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. *Haematologica*. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. PubMed PMID: 26069290; PubMed Central PMCID: PMC4800694.

Gnant M, Pfeiler G, Dubsy PC, Hubalek M, **Greil R**, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radacic V, Artner-Matuschek S, Fitzal F, Marth C, Sevela P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31. PubMed PMID: 26040499.

Gutjahr JC, **Greil R**, Hartmann TN. The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. *Front Immunol*. 2015 Apr 20;6:177. doi: 10.3389/fimmu.2015.00177. eCollection 2015. Review. PubMed PMID: 25941526; PubMed Central PMCID: PMC4403525.

Gassner FJ, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, Hartmann TN, Greil R, Geisberger R. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model. *Br J Haematol*. 2015 Aug;170(4):515-22. doi: 10.1111/bjh.13467. Epub 2015 May 4. PubMed PMID: 25940792; PubMed Central PMCID: PMC4687418.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, **Greil R**, Dubsy P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. *Ann Oncol*. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1. PubMed PMID: 25935792.

Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, Goldstein D, Mihaljevic B, Ilhan O, Ballova V, Hedenus M, Hsiao LT, Au WY, Burgstaller S, Weidinger G, Keil F, Dittrich C, Skrabs C, Klingler A, Chott A, Fridrik MA, **Greil R**; AGMT-NHL13 Investigators. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. *Haematologica*. 2015 Jul;100(7):955-63. doi: 10.3324/haematol.2015.125344. Epub 2015 Apr 24. PubMed PMID: 25911553; PubMed Central PMCID: PMC4486230.

Zaborsky N, Holler C, Geisberger R, Asslaber D, Gassner FJ, Egger V, Piñón-Hofbauer J, Kocher T, Hartmann TN, **Greil R**, Egle A. B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia. *Haematologica*. 2015 Aug;100(8):e307-10. doi: 10.3324/haematol.2015.124719. Epub 2015 Apr 24. PubMed PMID: 25911550; PubMed Central PMCID: PMC5004431.

Ganghammer S, Hutterer E, Hinterseer E, Brachtl G, Asslaber D, Krenn PW, Girbl T, Berghammer P, Geisberger R, Egle A, Zucchetto A, Kruschinski A, Gattei V, Chigaev A, **Greil R**, Hartmann TN. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21. *Oncotarget*.

2015 May 20;6(14):12048-60. PubMed PMID: 25895128; PubMed Central PMCID: PMC4494922.

Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de Castro G Jr, de Souza Viana L, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE; LUX-H&N 1 investigators. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16. PubMed PMID: 25892145.

Fitzal F, Filipits M, Rudas M, **Greil R**, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M. The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. *Br J Cancer.* 2015 Apr 14;112(8):1405-10. doi: 10.1038/bjc.2015.98. Epub 2015 Mar 24. PubMed PMID: 25867274; PubMed Central PMCID: PMC4402462.

Merkel O, Hamacher F, Griessler R, Grabner L, Schiefer AI, Prutsch N, Baer C, Egger G, Schleiderer M, Krenn PW, Hartmann TN, Simonitsch-Klupp I, Plass C, Staber PB, Moriggl R, Turner SD, **Greil R**, Kenner L. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. *J Pathol.* 2015 Aug;236(4):445-56. doi: 10.1002/path.4539. Epub 2015 Apr 27. PubMed PMID: 25820993; PubMed Central PMCID: PMC4557053.

Gampenrieder SP, Rinnerthaler G, **Greil R**. Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? *Breast Care (Basel).* 2014 Oct;9(5):323-30. doi: 10.1159/000368710. Review. PubMed PMID: 25759612; PubMed Central PMCID: PMC4322685.

Robak T, Huang H, Jin J, Zhu J, Liu T, Samoiloova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. *N Engl J Med.* 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. PubMed PMID: 25738670.

Troppan KT, Melchardt T, Deutsch A, Schlick K, Stojakovic T, Bullock MD, Reitz D, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, **Greil R**, Neumeister P, Egle A, Pichler M. The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients. *Eur J Haematol.* 2015 Dec;95(6):538-44. doi: 10.1111/ejh.12529. Epub 2015 Mar 26. PubMed PMID: 25677782.

Kern D, Regl G, Hofbauer SW, Altenhofer P, Achatz G, Dlugosz A, Schnidar H, **Greil R**, Hartmann TN, Aberger F. Hedgehog/GLI and PI3K signaling in the initiation and maintenance of chronic lymphocytic leukemia. *Oncogene.* 2015 Oct 16;34(42):5341-51. doi: 10.1038/onc.2014.450. Epub 2015 Feb 2. PubMed PMID: 25639866; PubMed Central PMCID: PMC4430320.

Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A, Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, **Greil R**, Sánchez-Guijo F, Fenaux P; European ALMA Investigators. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. *Leuk Res.* 2015 Mar;39(3):296-306.



doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31. PubMed PMID: 25601157.

Pleyer L, **Greil R**. Digging deep into "dirty" drugs - modulation of the methylation machinery. *Drug Metab Rev.* 2015 May;47(2):252-79. doi: 10.3109/03602532.2014.995379. Epub 2015 Jan 8. Review. PubMed PMID: 25566693; PubMed Central PMCID: PMC4733942.

Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, **Greil R**, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M. Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry. *Lung Cancer.* 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18. PubMed PMID: 25564398.

Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, Weltermann A, Thaler J, Hufnagl C, Gampenrieder SP, Rinnerthaler G, Ressler S, Ulmer H, **Greil R**. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. *Anticancer Res.* 2015 Jan;35(1):517-21. PubMed PMID: 25550597.

Hinterseer E, Stiefel O, Neureiter D, Kandler G, Vogt S, Hutter J, Strasser G, **Greil R**, Hartmann TN, Hopfinger G. VLA-4 and CXCR4 overexpression in bone marrow of an aleukemic B-cell acute lymphoblastic leukemia presenting with osteolytic bone lesions. *Leuk Lymphoma.* 2015;56(8):2465-7. doi: 10.3109/10428194.2014.999328. Epub 2015 Feb 9. PubMed PMID: 25547652.

Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, **Greil R**, Gisslinger H, Kralovics R. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. *Am J Hematol.* 2015 Apr;90(4):288-94. doi: 10.1002/ajh.23928. Epub 2015 Mar 2. PubMed PMID: 25545244; PubMed Central PMCID: PMC4657499.

Behringer K, Goergen H, Hitz F, Zijlstra JM, **Greil R**, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. *Lancet.* 2015 Apr 11;385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22. Erratum in: *Lancet.* 2015 Apr 11;385(9976):1396. PubMed PMID: 25539730.

Dittrich C, Fridrik MA, Koenigsberg R, Lee C, Goeldner RG, Hilbert J, **Greil R**. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. *Invest New Drugs.* 2015 Apr;33(2):409-22. doi: 10.1007/s10637-014-0201-7. Epub 2014 Dec 23. PubMed PMID: 25529193; PubMed Central PMCID: PMC4387274.

Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, Gottstein S, Geisen U, Schenk J, Scholz U, Schilling K, Neumeister P, Miesbach W, Manner D, **Greil R**, von Auer C, Krause M, Leimkühler K, Kalus U, Blumtritt JM,

Werwitzke S, Budde E, Koch A, Knöbl P. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. *Blood*. 2015 Feb 12;125(7):1091-7. doi: 10.1182/blood-2014-07-587089. Epub 2014 Dec 18. PubMed PMID: 25525118; PubMed Central PMCID: PMC4326770.

Blank PR, Filipits M, Dubsy P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, **Greil R**, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. *Pharmacoeconomics*. 2015 Feb;33(2):179-90. doi: 10.1007/s40273-014-0227-x. PubMed PMID: 25404424; PubMed Central PMCID: PMC4305105.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsy P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelde P, Ploner F, Bartsch R, Fesl C, **Greil R**; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. *Ann Oncol*. 2015 Feb;26(2):313-20. doi: 10.1093/annonc/mdu544. Epub 2014 Nov 17. PubMed PMID: 25403582.

Ludwig H, Rauch E, Kuehr T, Adam Z, Weißmann A, Kasparu H, Autzinger EM, Heintel D, **Greil R**, Poenisch W, Müldür E, Zojer N. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. *Haematologica*. 2015 Mar;100(3):385-91. doi: 10.3324/haematol.2014.115204. Epub 2014 Nov 14. PubMed PMID: 25398836; PubMed Central PMCID: PMC4349278.

Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, **Greil R**, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSSG). Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. *Anticancer Res*. 2014 Nov;34(11):6767-73. PubMed PMID: 25368289.

Hutterer E, Asslaber D, Caldana C, Krenn PW, Zucchetto A, Gattei V, **Greil R**, Hartmann TN. CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms. *Br J Haematol*. 2015 Apr;169(2):286-9. doi: 10.1111/bjh.13188. Epub 2014 Oct 17. PubMed PMID: 25322676; PubMed Central PMCID: PMC4406159.

Jöhrer K, Ploner C, Thangavadivel S, Wuggenig P, **Greil R**. Adipocyte-derived players in hematologic tumors: useful novel targets? *Expert Opin Biol Ther*. 2015 Jan;15(1):61-77. doi: 10.1517/14712598.2015.970632. Epub 2014 Oct 11. Review. PubMed PMID: 25308972.

Blons H, Emile JF, Le Malicot K, Julié C, Zaanani A, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Nørgård-Petersen L, Van Cutsem E, Lepage C, Zawadi MA, Salazar R, Laurent-Puig P, Taieb J; PETACC-8 Study Investigators. Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. *Ann Oncol*. 2014 Dec;25(12):2378-85. doi: 10.1093/annonc/mdu464. Epub 2014 Oct 6. Erratum in: *Ann Oncol*. 2015 Apr;26(4):822-5. PubMed PMID: 25294886.

Brodowicz T, Lang I, Kahan Z, **Greil R**, Beslija S, Stemmer SM, Kaufman B,

Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. *Br J Cancer*. 2014 Nov 25;111(11):2051-7. doi: 10.1038/bjc.2014.504. Epub 2014 Sep 30. PubMed PMID: 25268370; PubMed Central PMCID: PMC4260030.

Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Tränkenschuh W, Hopfinger G, Magnes T, Deutsch A, Neumeister P, Hackl H, **Greil R**, Pichler M, Egle A. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and  $\beta 2$ -microglobulin. *Br J Haematol*. 2015 Jan;168(2):239-45. doi: 10.1111/bjh.13116. Epub 2014 Sep 19. PubMed PMID: 25236324.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Galdes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermanand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. PubMed PMID: 25184863.

Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, Hebenstreit D, **Greil R**, Geisberger R. AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. *Eur J Immunol*. 2014 Dec;44(12):3747-57. doi: 10.1002/eji.201344421. Epub 2014 Oct 18. PubMed PMID: 25179679; PubMed Central PMCID: PMC4276288.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC; LUCID trial investigators. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. *Br J Haematol*. 2014 Nov;167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8. PubMed PMID: 25130401.

Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, Bond G, Pavlova S, Nüchel H, Merkel O, Ghia P, Montserrat E, Kaderi MA, Rosenquist R, Gaidano G, Dyer MJ, Söderkvist P, Linderholm M, Oscier D, Tvaruzkova Z, Pospisilova S, Dührsen U, **Greil R**, Döhner H, Stilgenbauer S, Zenz T; European Research Initiative on CLL (ERIC). MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. *Haematologica*. 2014 Aug;99(8):1285-91. doi: 10.3324/haematol.2013.101170. PubMed PMID: 25082786; PubMed Central PMCID: PMC4116826.

Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, Egle A, **Greil R**. Kasabach-Merritt phenomenon in hepatic angiosarcoma. *Br J Haematol*. 2014 Dec;167(5):716-8. doi: 10.1111/bjh.13049. Epub 2014 Jul 24. PubMed PMID: 25060176.

Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, Preusser M, **Greil R**, Hopfinger G. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? *Ann Hematol*. 2015 Feb;94(2):345-6. doi: 10.1007/s00277-014-2162-5. Epub 2014 Jul 24. PubMed PMID: 25055797.

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M,

Eckmayr J, Schmid T, Hilbe W, Fiegl M, **Greil R**. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemo-naïve patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). *Lung Cancer*. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3. PubMed PMID: 25043642.

Fastner G, Reitsamer R, Ziegler I, Zehentmayr F, Fussl C, Kopp P, Peintinger F, **Greil R**, Fischer T, Deutschmann H, Sedlmayer F. IOERT as anticipated tumor bed boost during breast-conserving surgery after neoadjuvant chemotherapy in locally advanced breast cancer--results of a case series after 5-year follow-up. *Int J Cancer*. 2015 Mar 1;136(5):1193-201. doi: 10.1002/ijc.29064. Epub 2014 Jul 10. PubMed PMID: 24995409.

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, **Greil R**, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC). Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. *Br J Haematol*. 2014 Nov;167(4):565-9. doi: 10.1111/bjh.13006. Epub 2014 Jun 30. PubMed PMID: 24975017.

Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, Schreder M, Tinchon C, Sliwa T, Lang A, Sperr WR, Krippel P, Geissler D, Voskova D, Schlick K, Thaler J, Machherndl-Spandl S, Theiler G, Eckmüller O, **Greil R**. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. *Ann Hematol*. 2014 Nov;93(11):1825-38. doi: 10.1007/s00277-014-2126-9. Epub 2014 Jun 21. PubMed PMID: 24951123; PubMed Central PMCID: PMC4176957.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2014 Jul;15(8):862-73. doi:10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11. PubMed PMID: 24928083.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivoy J, Clow F, James DF, Hillmen P; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31. PubMed PMID: 24881631; PubMed Central PMCID: PMC4134521.

Hohla F, Winder T, **Greil R**, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. *World J Gastroenterol*. 2014 May 28;20(20):6102-12. doi: 10.3748/wjg.v20.i20.6102. Review. PubMed PMID: 24876732; PubMed Central PMCID: PMC4033449.

Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, Beham-Schmid C, Weiss L, Neureiter D, Wenzl K, **Greil R**, Neumeister P, Pichler M. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. *Br J Cancer*. 2014 Jul 8;111(1):55-60. doi: 10.1038/bjc.2014.277. Epub 2014 May 29. PubMed PMID: 24874478; PubMed Central PMCID: PMC4090740.

Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, Grössinger EM, **Greil R**, Geisberger R. APOBEC3 signature mutations in chronic lymphocytic leukemia. *Leukemia*. 2014 Sep;28(9):1929-32. doi: 10.1038/leu.2014.160. Epub 2014 May 20. PubMed PMID: 24840555; PubMed Central PMCID: PMC4140768.

Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, Boekstegers A, Hopfinger G, Auberger J, Steinkirchner S, Pleyer L, **Greil R**, Egle A. Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. *Leuk Lymphoma*. 2015 Feb;56(2):353-60. doi: 10.3109/10428194.2014.916798. Epub 2014 Jun 25. PubMed PMID: 24798743.

Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorf A, **Greil R**, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. *Blood*. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283. Epub 2014 May 5. Erratum in: *Blood*. 2015 May 7;125(19):3037. PubMed PMID: 24797300.

Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, Moik M, **Greil R**, Egle A. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. *BMC Complement Altern Med*. 2014 Mar 30;14:115. doi: 10.1186/1472-6882-14-115. PubMed PMID: 24679099; PubMed Central PMCID: PMC3994275.

Girbl T, Lunzer V, **Greil R**, Namberger K, Hartmann TN. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. *Transfusion*. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28. PubMed PMID: 24673458; PubMed Central PMCID: PMC4215600.

Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, **Greil R**, Geisberger R. Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia. *Eur J Immunol*. 2014 Jul;44(7):2175-87. doi: 10.1002/eji.201343853. Epub 2014 Apr 15. PubMed PMID: 24668151; PubMed Central PMCID: PMC4209801.

EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan T, Wang Y, Wang Z, Darby S. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*. 2014 Jun 21;383(9935):2127-35. doi: 10.1016/S0140-6736(14)60488-8. Epub 2014 Mar 19. Erratum in: *Lancet*. 2014 Nov 22;384(9957):1848. PubMed PMID: 24656685; PubMed Central PMCID: PMC5015598.

Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, Rebhandl S, Catakovic K, Hartmann TN, **Greil R**, Geisberger R. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. *Haematologica*. 2014 May;99(5):67-9. doi: 10.3324/haematol.2013.098459. Epub 2014 Feb 21. PubMed PMID: 24561794; PubMed Central PMCID: PMC4008106.

Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, Girschikofsky M, Schreder M, Pfeilstocker M, Lang A, Sliwa T, Geissler D, Schlick K, Placher-Sorko G, Theiler G, Thaler J, Mitrovic M, Neureiter D, Valent P, **Greil R**. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. *Leuk Res*. 2014 Apr;38(4):475-83. doi: 10.1016/j.leukres.2014.01.006. Epub 2014 Jan 18. PubMed PMID: 24522248.

Filipits M, Nielsen TO, Rudas M, **Greil R**, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. *Clin Cancer Res*. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11. PubMed PMID: 24520097.

Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, Henschler R, Wallner M, Kerschbaum H, **Greil R**, Hartmann TN. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. *Blood*. 2014 Apr 3;123(14):2181-8. doi: 10.1182/blood-2013-08-523563. Epub 2014 Feb 5. PubMed PMID: 24501217.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaia V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. *Blood*. 2014 Apr 3;123(14):2157-60. doi: 10.1182/blood-2013-11-536557. Epub 2014 Jan 23. PubMed PMID: 24458439.

Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, **Greil R**, Oberkofler H, Eberle J. Human immunodeficiency virus type 2 infections in Austria. *Wien Klin Wochenschr*. 2014 Apr;126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18. PubMed PMID: 24442861.

Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, **Greil R**. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. *Ann Hematol*. 2014 Mar;93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18. PubMed PMID: 24441915.

Grössinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmölder J, Asslaber D, Hainzl S, Neureiter D, Egle A, Piñón-Hofbauer J, Hartmann TN, **Greil R**, Kerschbaum HH. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. *Leukemia*. 2014 Apr;28(4):954-8. doi: 10.1038/leu.2014.37. Epub 2014 Jan 20. PubMed PMID: 24441290.

Taylor N, Haschke-Becher E, **Greil R**, Strasser M, Oberkofler H. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections. *Antivir Ther*. 2014;19(5):449-54. doi: 10.3851/IMP2723. Epub 2014 Jan 16. PubMed PMID: 24430620.

Gnant M, **Greil R**, Hubalek M, Steger G. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion. *Breast Care (Basel)*. 2013 Aug;8(4):293-9. doi: 10.1159/000354121. Review. PubMed PMID: 24415983; PubMed Central PMCID: PMC3808223

Gampenrieder SP, Romeder F, Muß C, Pircher M, Ressler S, Rinnerthaler G, Bartsch R, Sattlberger C, Mlineritsch B, **Greil R**. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. *Anticancer Res*. 2014 Jan;34(1):227-33. PubMed PMID: 24403467.

Bezan A, Hohla F, Meissnitzer T, **Greil R**. Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. *BMC Cancer*. 2013 Dec 31;13:618. doi: 10.1186/1471-2407-13-618. PubMed PMID: 24380380; PubMed Central PMCID: PMC3880167.

Steger GG, **Greil R**, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSCG). Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSCG-24). *Ann Oncol*. 2014 Feb;25(2):366-71. doi: 10.1093/annonc/mdt508. Epub 2013 Dec 16. PubMed PMID: 24347519.

Gnant M, Filipits M, **Greil R**, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSCG-8 trial treated with adjuvant endocrine therapy alone. *Ann Oncol*. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16. PubMed PMID: 24347518.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. PubMed PMID: 24331154.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, **Greil R**, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. *Mod Pathol*. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6. PubMed PMID: 24309322.

Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, **Greil R**, Egle A. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. *Ann Oncol*. 2014 Jan;25(1):171-6. doi: 10.1093/annonc/mdt481. Epub 2013 Dec 3. PubMed PMID: 24299961.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, **Greil R**, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. *Ann Hematol*. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30. PubMed PMID: 24292560.

Brachtl G, Piñón Hofbauer J, **Greil R**, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. *Ann Hematol*. 2014 Mar;93(3):361-74. doi: 10.1007/s00277-013-1967-y. Epub 2013 Nov 28. Review. PubMed PMID: 24288111; PubMed Central PMCID: PMC4032465.

Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y; SENSE Study Group. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. *J Antimicrob Chemother*. 2014 Apr;69(4):1090-7. doi: 10.1093/jac/dkt474. Epub 2013 Nov 27. PubMed PMID: 24284781.

Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, Neureiter D, Troch M, **Greil R**, Egle A. Pleural decortication of a marginal zone lymphoma. *Ann Hematol*. 2014 Jul;93(7):1253-4. doi: 10.1007/s00277-013-1960-5. Epub 2013 Nov 22. PubMed PMID: 24263860.

Melchardt T, Weiss L, Pleyer L, Steinkirchner S, Auberger J, Hopfinger G, **Greil R**, Egle A. Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome. *Oncol Lett*. 2013 Dec;6(6):1756-1758. Epub 2013 Oct 15. PubMed PMID: 24260071; PubMed Central PMCID: PMC3834563.

Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stättner S, Hauser-Kronberger C, Ulmer H, **Greil R**. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. *Int J Oncol*. 2014 Jan;44(1):319-26. doi: 10.3892/ijo.2013.2176. Epub 2013 Nov 15. PubMed PMID: 24247204.

Huemer F, Gampenrieder SP, Schlattau A, **Greil R**. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer? *Clin Breast Cancer*. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28. PubMed PMID: 24246725.

Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, **Greil R**, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. *Blood*. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. Epub 2013 Nov 13. PubMed PMID: 24227817; PubMed Central PMCID: PMC3924931.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, **Greil R**, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSSG). The EndoPredict score provides prognostic information



on late distant metastases in ER+/HER2- breast cancer patients. *Br J Cancer*. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24. PubMed PMID: 24157828; PubMed Central PMCID: PMC3859949.

Schlick K, Datz L, Hohla F, **Greil R**, Hopfinger G. [71-year old woman with neutropenic fever during chemotherapy]. *Dtsch Med Wochenschr*. 2013 Oct;138(41):2091-2. doi: 10.1055/s-0033-1349528. Epub 2013 Oct 1. German. PubMed PMID: 24085362.

**Greil R**, Hiddemann W. [Successful cancer therapy: chance and challenges]. *Dtsch Med Wochenschr*. 2013 Oct;138(41):2083. doi: 10.1055/s-0033-1349623. Epub 2013 Oct 1. German. PubMed PMID: 24085360.

Gampenrieder SP, Rinnerthaler G, **Greil R**. Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and future. *J Oncol*. 2013;2013:732047. doi: 10.1155/2013/732047. Epub 2013 Aug 20. Review. PubMed PMID: 24027583; PubMed Central PMCID: PMC3762209.

Stenner-Liewen F, Grünwald V, **Greil R**, Porta C. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma. *Expert Rev Anticancer Ther*. 2013 Sep;13(9):1021-33. doi: 10.1586/14737140.2013.833684. Epub 2013 Sep 12. Review. PubMed PMID: 24024788.

Taylor N, Grabmeier-Pfistershammer K, Egle A, **Greil R**, Rieger A, Ledergerber B, Oberkofler H. Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. *PLoS One*. 2013 Aug 30;8(8):e74024. doi: 10.1371/journal.pone.0074024. eCollection 2013. PubMed PMID: 24023696; PubMed Central PMCID: PMC3758316.

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsy P, **Greil R**, Steger G, Samonigg H, Fesl C, Jakesz R. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. *Br J Cancer*. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18. PubMed PMID: 23868011; PubMed Central PMCID: PMC3738117.

Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, **Greil R**, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. *J Clin Oncol*. 2013 Aug 10;31(23):2870-8. doi: 10.1200/JCO.2012.43.3391. Epub 2013 Jul 15. PubMed PMID: 23857972.

Kubicka S, **Greil R**, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. *Ann Oncol*. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. PubMed PMID: 23852309.

Weiss L, Hufnagl C, **Greil R**. Circulating tumor DNA to monitor metastatic

breast cancer. *N Engl J Med*. 2013 Jul 4;369(1):93. doi: 10.1056/NEJMc1306040#SA2. PubMed PMID: 23822790.

Baselga J, Gómez P, **Greil R**, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. *J Clin Oncol*. 2013 Jul 10;31(20):2586-92. doi: 10.1200/JCO.2012.46.2408. Epub 2013 Jun 3. PubMed PMID: 23733761.

Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, von Lilienfeld-Toal M, Brugger W, Derigs HG, Kremers S, **Greil R**, Raghavachar A, Ringhoffer M, Salih HR, Wattad M, Kirchen HG, Runde V, Heil G, Petzer AL, Girschikofsky M, Heuser M, Kayser S, Goehring G, Teleanu MV, Schlegelberger B, Ganser A, Krauter J, Bullinger L, Döhner H, Döhner K. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). *Blood*. 2013 Jun 6;121(23):4769-77. doi: 10.1182/blood-2012-10-461624. Epub 2013 Apr 30. PubMed PMID: 23632886.

Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, Lang A, Krippel P, Sliwa T, Egle A, Linkesch W, Voskova D, Angermann H, **Greil R**. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. *J Hematol Oncol*. 2013 Apr 29;6:32. doi: 10.1186/1756-8722-6-32. PubMed PMID: 23627920; PubMed Central PMCID: PMC3655844.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, **Greil R**, Moore N, Prot S, Pallaud C, Semiglazov V. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. *J Clin Oncol*. 2013 May 10;31(14):1719-25. doi: 10.1200/JCO.2012.44.7912. Epub 2013 Apr 8. PubMed PMID: 23569311.

Pfeiler G, Stöger H, Dubsy P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, **Greil R**, Fesl C, Gnant M; ABCSG. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. *Br J Cancer*. 2013 Apr 16;108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19. PubMed PMID: 23511562; PubMed Central PMCID: PMC3629426.

Böll B, Görden H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, **Greil R**, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. *J Clin Oncol*. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18. PubMed PMID: 23509310.

Lang I, Brodowicz T, Ryvo L, Kahan Z, **Greil R**, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for

HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. *Lancet Oncol.* 2013 Feb;14(2):125-33. doi: 10.1016/S1470-2045(12)70566-1. Epub 2013 Jan 10. PubMed PMID: 23312888.

Namberger K, Weiss L, Krause B, Melchardt T, **Greil R**. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p. *Eur J Haematol.* 2013 Apr;90(4):349-50. doi: 10.1111/ejh.12065. Epub 2013 Feb 14. PubMed PMID: 23278160.

Lass-Flörl C, Mutschlechner W, Aigner M, Grif K, Marth C, Girschikofsky M, Grander W, **Greil R**, Russ G, Cerkl P, Eller M, Kropshofer G, Eschertzhuber S, Kathrein H, Schmid S, Beer R, Lorenz I, Theurl I, Nachbaur D. Utility of PCR in diagnosis of invasive fungal infections: real-life data from a multicenter study. *J Clin Microbiol.* 2013 Mar;51(3):863-8. doi: 10.1128/JCM.02965-12. Epub 2012 Dec 26. PubMed PMID: 23269732; PubMed Central PMCID: PMC3592065.

Taylor N, Melchardt T, Grundbichler M, Strasser M, Egle A, **Greil R**. Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfecting patient. *Ann Hematol.* 2013 Jul;92(7):1001-2. doi: 10.1007/s00277-012-1659-z. Epub 2012 Dec 28. PubMed PMID: 23269533.

Auberger J, Vogt S, Hopfinger G, Clausen J, **Greil R**. Topical evening primrose oil for reduction of bortezomib-induced skin reactions. *Ann Hematol.* 2013 Jul;92(7):995-6. doi: 10.1007/s00277-012-1656-2. Epub 2012 Dec 22. PubMed PMID: 23262668.

Auberger J, **Greil R**, Lass-Flörl C. What paths are open for tackling increasing azole resistance in *Aspergillus* in the clinic? *Expert Rev Anti Infect Ther.* 2012 Nov;10(11):1229-31. doi: 10.1586/eri.12.126. PubMed PMID: 23241178.

Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, **Greil R**, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilbourn RM, Ames MM, Ingle JN. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSSG) 8. *Clin Cancer Res.* 2013 Jan 15;19(2):500-7. doi: 10.1158/1078-0432.CCR-12-2153. Epub 2012 Dec 4. PubMed PMID: 23213055; PubMed Central PMCID: PMC3548984.

Melchardt T, Weiss L, **Greil R**, Egle A. Viral infections and their management in patients with chronic lymphocytic leukemia. *Leuk Lymphoma.* 2013 Aug;54(8):1602-13. doi: 10.3109/10428194.2012.755178. Epub 2013 Jan 3. Review. PubMed PMID: 23206225.

Asslaber D, Grössinger EM, Girbl T, Hofbauer SW, Egle A, Weiss L, **Greil R**, Hartmann TN. Mimicking the microenvironment in chronic lymphocytic leukaemia - where does the journey go? *Br J Haematol.* 2013 Mar;160(5):711-4. doi: 10.1111/bjh.12151. Epub 2012 Dec 4. PubMed PMID: 23205585.

Bennouna J, Sastre J, Arnold D, Österlund P, **Greil R**, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol.* 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. PubMed PMID: 23168366.

Girbl T, Hinterseer E, Grössinger EM, Asslaber D, Oberascher K, Weiss L, Hauser-Kronberger C, Neureiter D, Kerschbaum H, Naor D, Alon R, **Greil R**, Hartmann TN. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. *Cancer Res.* 2013 Jan 15;73(2):561-70. doi: 10.1158/0008-5472.CAN-12-2749. Epub 2012 Nov 1. PubMed PMID: 23117883.

Ludwig H, Viterbo L, **Greil R**, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. *J Clin Oncol.* 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22. PubMed PMID: 23091109.

Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, **Greil R**, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. *Ann Oncol.* 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3. PubMed PMID: 23035151; PubMed Central PMCID: PMC3574544.

Thaler J, Karthaus M, Mineur L, **Greil R**, Letocha H, Hofheinz R, Fernebro E, Gamelin E, Baños A, Köhne CH. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. *BMC Cancer.* 2012 Sep 29;12:438. doi: 10.1186/1471-2407-12-438. PubMed PMID: 23020584; PubMed Central PMCID: PMC3520865.

Hopfinger G, Griessl R, Sift E, Taylor N, Kenner L, **Greil R**, Merkel O. Novel treatment avenues for peripheral T-cell lymphomas. *Expert Opin Drug Discov.* 2012 Dec;7(12):1149-63. doi: 10.1517/17460441.2012.727392. Epub 2012 Sep 24. Review. PubMed PMID: 22998641.

Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, Fridrik M, Müllauer L, **Greil R**, Raderer M. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentöse Tumortherapie. *Haematologica.* 2013 Feb;98(2):264-8. doi: 10.3324/haematol.2012.072587. Epub 2012 Sep 14. PubMed PMID: 22983582; PubMed Central PMCID: PMC3561434.

Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, **Greil R**, Bachtiry B, Tinchon C, Anderhuber W, Burian M, Kasperek AK, Elsässer W, Kainz H, Riedl R, Kopp M, Kornek G. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. *Eur J Cancer.* 2013 Jan;49(2):352-9. doi: 10.1016/j.ejca.2012.08.004. Epub 2012 Sep 14. PubMed PMID: 22981499.

Reinacher-Schick A, Schulmann K, Modest DP, Bruns N, Graeven U, Jaworska M, **Greil R**, Porschen R, Arnold D, Schmiegel W, Tannapfel A. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. *BMC Cancer.* 2012 Aug 9;12:349. doi:

10.1186/1471-2407-12-349. PubMed PMID: 22876876; PubMed Central PMCID: PMC3442969.

Psenak O, Studnicka-Benke A, **Greil R**. [Safety of immunosuppressants]. *Z Rheumatol*. 2012 Jul;71(5):420-9. doi: 10.1007/s00393-012-0990-z. German. PubMed PMID: 22772888.

Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, **Greil R**, Zielinski CC, Bartsch R. Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. *Oncologist*. 2012;17(7):e13-7. doi: 10.1634/theoncologist.2012-0115. Epub 2012 Jun 27. PubMed PMID: 22744818; PubMed Central PMCID: PMC3399659.

Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schleder M, Steurer M, Kenner L, **Greil R**. Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia. *Leukemia*. 2012 Dec;26(12):2508-16. doi: 10.1038/leu.2012.147. Epub 2012 Jun 1. PubMed PMID: 22743622.

Lang I, Inbar MJ, Kahán Z, **Greil R**, Beslija S, Stemmer SM, Kaufman B, Zvirbulė Z, Steger GG, Messinger D, Brodowicz T, Zielinski C. Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. *Eur J Cancer*. 2012 Nov;48(17):3140-9. doi: 10.1016/j.ejca.2012.04.022. Epub 2012 May 26. PubMed PMID: 22640829.

Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med*. 2012 May 10;366(19):1759-69. doi: 10.1056/NEJMoa1112704. Erratum in: *N Engl J Med*. 2012 Jul 19;367(3):285. PubMed PMID: 22571200.

Jäger U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, **Greil R**; Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT) Investigators. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. *Haematologica*. 2012 Sep;97(9):1431-8. Epub 2012 Apr 17. PubMed PMID: 22511498; PubMed Central PMCID: PMC3436246.